tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Actinium Pharmaceuticals (DE:7AY1)
:7AY1
Germany Market
7AY1
Actinium Pharmaceuticals
Overview
Analyst Forecasts
Dividends
Earnings
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
DE:7AY1 Chart

Actinium Pharmaceuticals (7AY1) Stock News & Sentiment

Compare
1 Followers
Levi & Korsinsky LLP Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline
Premium
Class Action
Levi & Korsinsky LLP Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline
25d ago
ATNM
Actinium Pharmaceuticals: Strong Financial Health and Promising Clinical Progress Drive Buy Rating
Premium
Ratings
Actinium Pharmaceuticals: Strong Financial Health and Promising Clinical Progress Drive Buy Rating
27d ago
ATNM
Actinium Pharmaceuticals: Strategic Advancements and Financial Stability Signal Undervalued Opportunity
Premium
Ratings
Actinium Pharmaceuticals: Strategic Advancements and Financial Stability Signal Undervalued Opportunity
1M ago
ATNM
Promising Outlook for Actimab-A in AML: Buy Rating Backed by Strategic Collaborations and Upcoming Trials
Premium
Ratings
Promising Outlook for Actimab-A in AML: Buy Rating Backed by Strategic Collaborations and Upcoming Trials
1M ago
ATNM
Actinium Pharmaceuticals: Promising Clinical Advancements and Strong Financial Outlook Support Buy Rating
Premium
Ratings
Actinium Pharmaceuticals: Promising Clinical Advancements and Strong Financial Outlook Support Buy Rating
1M ago
ATNM
Promising Phase 1b Trial Results for Actinium Pharmaceuticals’ Actimab-A in r/r AML Support Buy Rating
Premium
Ratings
Promising Phase 1b Trial Results for Actinium Pharmaceuticals’ Actimab-A in r/r AML Support Buy Rating
1M ago
ATNM
Actinium Pharmaceuticals: Strategic Clinical Advancements and Innovative Trials Drive Buy Rating
Premium
Ratings
Actinium Pharmaceuticals: Strategic Clinical Advancements and Innovative Trials Drive Buy Rating
1M ago
ATNM
More DE:7AY1 News >

7AY1 News on the Web

Levi & Korsinsky LLP Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Tonix Pharma (TNXP)
TipRanks News
Neutral
Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML
Yahoo Finance
Neutral
H.C. Wainwright Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)
TipRanks News
Bullish
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Bullish
Optimistic Buy Rating for Actinium Pharmaceuticals Driven by Strategic Initiatives and Promising Clinical Developments
TipRanks News
Bullish
Optimistic Buy Rating for Actinium Pharmaceuticals Driven by Strategic Progress and Promising Pipeline
TipRanks News
Bullish
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
Zacks
Neutral

News Score - Last 7 Days

Neutral
DE:7AY1
Sector Average
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
This Week59%
Sector Average58%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:7AY1’s Media Buzz Sentiment?
Currently, no data Available
What is DE:7AY1’s weekly average amount of articles?
Currently, no data Available
What is DE:7AY1’s News Sentiment?
59% of articles about DE:7AY1 were positive this week, compared to its sector average of 58%.
    Healthcare Stocks that are Trending in the News
    URGNUrogen Pharma
    HRTXHeron Therapeutics
    JAGXJaguar Animal Health
    EWEdwards Lifesciences
    ACRSAclaris Therapeutics
    Showing the stocks with the most bullish news sentiment over the past week

    Become an Expert with TipRanks Premium

    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis
    Subscribe NowSee Plans & Pricing